Cohort study: Piperacillin/tazobactam linked to increased risk of acute kidney injury when compared to cefepime or meropenem
15 Jan, 2021 | 08:24h | UTC
Commentary on Twitter
NEW ?? #CID @IDSAInfo
Risk of AKI & CDI with piperacillin/tazobactam, cefepime and meropenem with or without vancomycin #IDTwitter @danlivorsi
TZP ⬆️ AKI risk, which was exacerbated by concurrent vancomycin.
FEP&MER ⬆️CDI risk relative to TZP. https://t.co/0pIurl7A7w pic.twitter.com/ZjjvN2rkWP— Antibiotic Steward? Bassam Ghanem (@ABsteward) December 31, 2020